ASCO GU 2019: Health-Related Quality of Life Reporting in Phase III Randomized Controlled Trials of Metastatic Prostate Adenocarcinoma and Urothelial Carcinoma

San Francisco, CA ( Health-related quality of life (HRQOL) reflects the patient’s subjective perception of several functional domains: physical, psychological, cognitive, social, and general well-being. HRQOL is central to assessment of efficacy and guides decision at a regulatory level, especially when drug impacts on overall survival is limited.

ASCO GU 2019: Study of Durvalumab Given with Chemotherapy, Durvalumab in Combination with Tremelimumab Given with Chemotherapy, or Chemotherapy in Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer

San Francisco, CA ( Bladder cancer is the ninth most common cancer diagnosis worldwide. Over 5% of patients present with metastatic disease. Approximately 70% present with non-muscle invasive disease (NMIBC) and 30% are muscle invasive (MIBC). Nearly 40% of NMIBC progress to MIBC. Combining immunotherapy with chemotherapy could be a key option for improving clinical outcomes in advanced urothelial carcinoma patients.

ASCO GU 2019: Phase II Study of Ribociclib in Men with Unresectable, Incurable Teratoma with Recent Progression

San Francisco, CA ( Most patients with teratoma are managed by surgery and no standard medical therapy exists for progressive and unresectable teratoma. Little progress has been made in the treatment of progressive and unresectable disease, and no standard therapy exits. Teratomas have a functional expression of retinoblastoma protein, and clinical activity was observed with CDK4/6 inhibition.1 Ribociclib is an orally bioavailable small molecule inhibitor of CDK 4/6, approved for the use in patients with hormone receptor positive, human epidermal growth factor 2 negative advanced breast cancer. Given its mechanism of action, it may have potential therapeutic activity in patients with teratomas. 

ASCO GU 2019: Malignant Pheochromocytoma: Comprehensive Genomic Profiling Study

San Francisco, CA ( Genomic profiling of large datasets of different malignancies has begun to reveal information beyond what basic immunohistochemistry and histology can offer. With increasing knowledge regarding the genomics of these malignancies, novel therapies are being developed and are able to be utilized across disease spaces.

ASCO GU 2019: Accelerated versus Standard BEP Chemotherapy for Adult and Pediatric Male and Female Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumors

San Francisco, CA ( Bleomycin, Etoposide, and Cisplatin (BEP) *4 as three weekly cycles are the standard of care first-line treatment for patients with metastatic germ cell with poor prognostic features. High dose chemotherapy and more complex regimens have failed to improve cure rates and are more toxic. Accelerating regimens of standard three weekly chemotherapy to 2-weekly cycles has improved cure rates in other malignancies. Phase 1 and 2 data have shown that it is safe and feasible to accelerate standard chemotherapy in germ cell tumors.

ASCO GU 2019: The PRIMETEST Trial: Interim Analysis of a Phase II Trial for Primary Retroperitoneal Lymph Node Dissection (RPLND) in Stage II A/B Seminoma Patients without Adjuvant Treatment

San Francisco, CA ( Seminoma (one of two predominant histologic subtypes of testicular cancer), when presenting with metastatic disease, specifically with isolated retroperitoneal lymphadenopathy, is typically treated with external beam radiation therapy (XRT) or systemic chemotherapy (3 cycles BEP or 4 cycles EP). There has been little change in these recommendations over the last few decades. However, with greater follow-up and interest in the long-term morbidity of these systemic therapies (toxicities often present many years), there is growing interest in alternative therapies.

ASCO GU 2019: Sacituzumab Govitecan (IMMU-132) in Patients with Previously Treated Metastatic Urothelial CancerUroiT

San Francisco, CA ( Patients with metastatic urothelial carcinoma (mUC) have a poor prognosis, and those who progress after platinum chemotherapy and immunotherapy with programmed death ligand 1 (PD-1)/(PD-L1) inhibitors have limited treatment options. Sacituzumab govitecan (SG) is a novel antibody-drug conjugate. The antibody is humanized anti-Trop2 and it is attached to the active metabolite of irinotecan, a cytotoxic chemotherapy agent. The combination drug targets Trop-2 which is overexpressed in aggressive epithelial cancers including up to 83% of UC.
Page 1 of 3

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.